Total Payments
$2,101
2024 Payments
$148.11
Companies
15
Transactions
72
Medicare Patients
2,508
Medicare Billing
$444,347
Payment Breakdown by Category
Food & Beverage$2,031 (96.7%)
Education$69.99 (3.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,031 | 71 | 96.7% |
| Education | $69.99 | 1 | 3.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan Inc. | $504.76 | 22 | $0 (2019) |
| Janssen Biotech, Inc. | $281.09 | 16 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $249.99 | 2 | $0 (2018) |
| ABBVIE INC. | $171.11 | 7 | $0 (2024) |
| Theravance Biopharma Inc. | $148.65 | 3 | $0 (2017) |
| ViiV Healthcare Company | $140.13 | 7 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $124.07 | 1 | $0 (2022) |
| Biosense Webster, Inc. | $119.09 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $83.44 | 5 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $80.00 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $148.11 | 6 | ViiV Healthcare Company ($55.16) |
| 2023 | $193.48 | 5 | Janssen Pharmaceuticals, Inc ($80.00) |
| 2022 | $182.52 | 4 | Teva Pharmaceuticals USA, Inc. ($124.07) |
| 2021 | $141.27 | 4 | AbbVie Inc. ($71.28) |
| 2020 | $33.15 | 2 | Janssen Biotech, Inc. ($33.15) |
| 2019 | $175.26 | 11 | Janssen Biotech, Inc. ($79.69) |
| 2018 | $604.39 | 17 | Avanir Pharmaceuticals, Inc. ($249.99) |
| 2017 | $622.85 | 23 | Allergan Inc. ($389.22) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $27.79 | General |
| Category: HIV | ||||||
| 10/23/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $27.37 | General |
| Category: HIV | ||||||
| 06/19/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/13/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $29.35 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/30/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $20.69 | General |
| 01/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.56 | General |
| 10/03/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $34.88 | General |
| Category: Infections and Infectious Diseases | ||||||
| 08/15/2023 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/14/2023 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: HIV | ||||||
| 06/01/2023 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $80.00 | General |
| Category: Neuroscience | ||||||
| 01/11/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $31.09 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/13/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.62 | General |
| 06/09/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/30/2022 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $124.07 | General |
| Category: Central Nervous System | ||||||
| 01/11/2022 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 12/03/2021 | Janssen Products, LP | SYMTUZA (Drug) | Education | In-kind items and services | $69.99 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 10/21/2021 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $28.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/14/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/12/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $26.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/25/2020 | Janssen Biotech, Inc. | SYMTUZA (Drug), JULUCA | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 01/07/2020 | Janssen Biotech, Inc. | SYMTUZA (Drug) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 10/16/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/03/2019 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $12.57 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/01/2019 | Janssen Biotech, Inc. | Symtuza (Drug), Juluca | Food and Beverage | In-kind items and services | $16.69 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 09/26/2019 | Janssen Biotech, Inc. | Symtuza (Drug), Juluca | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: Infectious Diseases & Vaccines | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 681 | 1,517 | $228,803 | $117,302 |
| 2022 | 5 | 619 | 1,475 | $213,828 | $104,947 |
| 2021 | 6 | 530 | 1,354 | $193,191 | $98,448 |
| 2020 | 6 | 678 | 1,718 | $239,536 | $123,649 |
Total Patients
2,508
Total Services
6,064
Medicare Billing
$444,347
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 338 | 1,123 | $133,597 | $73,289 | 54.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 145 | 147 | $49,247 | $20,413 | 41.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 105 | 110 | $24,970 | $11,996 | 48.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 45 | 62 | $10,664 | $6,047 | 56.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 50 | $8,700 | $4,499 | 51.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 21 | 25 | $1,625 | $1,059 | 65.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 340 | 1,156 | $137,554 | $68,321 | 49.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 162 | 176 | $40,321 | $19,448 | 48.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 69 | 69 | $23,115 | $10,301 | 44.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 55 | $9,570 | $5,254 | 54.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 19 | $3,268 | $1,624 | 49.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 279 | 1,066 | $126,877 | $64,792 | 51.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 135 | 148 | $33,979 | $17,101 | 50.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 59 | 59 | $19,706 | $9,978 | 50.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 44 | $7,656 | $4,061 | 53.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 24 | $4,128 | $2,100 | 50.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 13 | 13 | $845.00 | $416.09 | 49.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 363 | 1,339 | $159,883 | $82,791 | 51.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 166 | 171 | $38,817 | $20,084 | 51.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 57 | 57 | $19,095 | $10,044 | 52.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 53 | 77 | $13,244 | $6,674 | 50.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 22 | 33 | $5,742 | $2,670 | 46.5% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 17 | 41 | $2,755 | $1,385 | 50.3% |
About Dr. Simon Edelstein, MD
Dr. Simon Edelstein, MD is a Infectious Disease healthcare provider based in Aventura, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417992751.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Simon Edelstein, MD has received a total of $2,101 in payments from pharmaceutical and medical device companies, with $148.11 received in 2024. These payments were reported across 72 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($2,031).
As a Medicare-enrolled provider, Edelstein has provided services to 2,508 Medicare beneficiaries, totaling 6,064 services with total Medicare billing of $444,347. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Aventura, FL
- Active Since 06/19/2006
- Last Updated 10/26/2009
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1417992751
Products in Payments
- AVYCAZ (Drug) $317.62
- NUEDEXTA (Drug) $249.99
- DALVANCE (Drug) $206.12
- VIBATIV (Drug) $148.65
- Symtuza (Drug) $135.22
- AUSTEDO (Drug) $124.07
- SYMTUZA (Drug) $123.22
- VRAYLAR (Drug) $121.17
- Carto 3 System (Device) $119.09
- PREZCOBIX (Drug) $92.64
- DOVATO (Drug) $81.03
- SPRAVATO (Drug) $80.00
- Fetroja (Drug) $63.23
- JULUCA (Drug) $45.67
- TEFLARO (Drug) $30.96
- CRESEMBA (Drug) $14.98
- TRIUMEQ (Drug) $13.43
- ISENTRESS (Drug) $11.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.